Myelodysplastic Syndrome Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight

Myelodysplastic Syndrome Treatment Market

(Albany, USA) DelveInsight’s “Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myelodysplastic Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myelodysplastic Syndrome Market Forecast

Some of the key facts of the Myelodysplastic Syndrome Market Report: 

• The total Myelodysplastic Syndrome Market Size in 2023 was more than USD 2,800 Million in the 7MM, and the largest market size was occupied by the US.
•  In January 2024, Faron Pharmaceuticals announced that the first patient has been dosed in Phase II of the BEXMAB trial that evaluates the safety and efficacy of bexmarilimab, in combination with standard of care (SoC) in patients with hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndrome (MDS). 
• In October 2023, Servier announced that the US Food and Drug Administration (FDA) has approved TIBSOVO (ivosidenib tablets) for the treatment of patients with isocitrate dehydrogenase 1 (IDH1)- mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS). 
• In August 2023, Bristol Myers Squibb announced that the US FDA has approved REBLOZYL (luspatercept-aamt) for the treatment of anemia without previous erythropoiesis stimulating agent use (ESAnaïve) in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell (RBC) transfusions.
• According to DelveInsight, the collective incident population of MDS across the 7MM was approximately 42,000 in 2023. Projections suggest that these figures will rise by 2034.
• In the EU4 and the UK, Germany recorded the highest incident population of MDS, totaling around 4,500 cases, followed by France. Conversely, Spain reported the lowest incident population of MDS in 2023.
• In the United States, the predominant subtype of MDS cases was RAEB/MDS-EB, representing approximately 7,000 cases in 2023. Projections indicate an anticipated increase in these numbers by 2034.
• Key Myelodysplastic Syndrome Companies: University Hospital, Grenoble, Kind Pharmaceuticals LLC, Otsuka Beijing Research Institute, Agios Pharmaceuticals, Bristol-Myers Squibb, Syros Pharmaceuticals, H. Lee Moffitt Cancer Center, Novartis, Acceleron Pharma, Celgene, Eli Lilly and Company, Geron Corporation, Amgen, Astex Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, and others
• Key Myelodysplastic Syndrome Therapies: Deferasirox, AND017, Decitabine, AG-946, Luspatercept, Tamibarotene, INCB024360, MBG453, ACE-536, Durvalumab, Galunisertib, Imetelstat, Darbepoetin Alfa, ASTX727 LD, Epoetin beta, Talacotuzumab, and others
• The Myelodysplastic Syndrome epidemiology based on gender analyzed that Myelodysplastic Syndrome is more common in men as compared to women
• The Myelodysplastic Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myelodysplastic Syndrome pipeline products will significantly revolutionize the Myelodysplastic Syndrome market dynamics.

Myelodysplastic Syndrome Overview

Myelodysplastic syndromes (MDS) are a group of disorders characterized by abnormal development and function of blood cells in the bone marrow. In MDS, the bone marrow fails to produce enough healthy blood cells, including red blood cells, white blood cells, and platelets. This results in cytopenias (low blood cell counts) and can lead to symptoms such as fatigue, weakness, shortness of breath, frequent infections, and easy bruising or bleeding.

Get a Free sample for the Myelodysplastic Syndrome Market Report: https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market

Myelodysplastic Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myelodysplastic Syndrome Epidemiology Segmentation:

The Myelodysplastic Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Myelodysplastic Syndrome
• Prevalent Cases of Myelodysplastic Syndrome by severity
• Gender-specific Prevalence of Myelodysplastic Syndrome
• Diagnosed Cases of Episodic and Chronic Myelodysplastic Syndrome

Download the report to understand which factors are driving Myelodysplastic Syndrome epidemiology trends @ Myelodysplastic Syndrome Epidemiology Forecast

Myelodysplastic Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myelodysplastic Syndrome market or expected to get launched during the study period. The analysis covers Myelodysplastic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myelodysplastic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myelodysplastic Syndrome Therapies and Key Companies

• Deferasirox: University Hospital, Grenoble
• AND017: Kind Pharmaceuticals LLC
• Decitabine: Otsuka Beijing Research Institute
• AG-946: Agios Pharmaceuticals
• Luspatercept: Bristol-Myers Squibb
• Tamibarotene: Syros Pharmaceuticals
• Luspatercept: Bristol-Myers Squibb
• INCB024360: H. Lee Moffitt Cancer Center
• MBG453: Novartis
• ACE-536: Acceleron Pharma
• Durvalumab: Celgene
• Galunisertib: Eli Lilly and Company
• Imetelstat: Geron Corporation
• Darbepoetin Alfa: Amgen
• ASTX727 LD: Astex Pharmaceuticals
• Epoetin beta: Hoffmann-La Roche
• Talacotuzumab: Janssen Research & Development

Discover more about therapies set to grab major Myelodysplastic Syndrome market share @ Myelodysplastic Syndrome Treatment Market

Myelodysplastic Syndrome Market Strengths

• The current treatment options for MDS include curative, supportive, and symptomatic treatments that are easily and widely available in the market, along with their generics.

Myelodysplastic Syndrome Market Opportunities

• Various studies have highlighted the role of multiple gene mutations like RUNX1, TP53, TET2, DNMT3A, ASXL1, and others in MDS. Developing therapies with targetable mutations will open a new window of opportunity for companies developing therapies for MDS.

Scope of the Myelodysplastic Syndrome Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Myelodysplastic Syndrome Companies: University Hospital, Grenoble, Kind Pharmaceuticals LLC, Otsuka Beijing Research Institute, Agios Pharmaceuticals, Bristol-Myers Squibb, Syros Pharmaceuticals, H. Lee Moffitt Cancer Center, Novartis, Acceleron Pharma, Celgene, Eli Lilly and Company, Geron Corporation, Amgen, Astex Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, and others
• Key Myelodysplastic Syndrome Therapies: Deferasirox, AND017, Decitabine, AG-946, Luspatercept, Tamibarotene, INCB024360, MBG453, ACE-536, Durvalumab, Galunisertib, Imetelstat, Darbepoetin Alfa, ASTX727 LD, Epoetin beta, Talacotuzumab, and others
• Myelodysplastic Syndrome Therapeutic Assessment: Myelodysplastic Syndrome current marketed and Myelodysplastic Syndrome emerging therapies
• Myelodysplastic Syndrome Market Dynamics: Myelodysplastic Syndrome market drivers and Myelodysplastic Syndrome market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Myelodysplastic Syndrome Unmet Needs, KOL’s views, Analyst’s views, Myelodysplastic Syndrome Market Access and Reimbursement 

To know more about Myelodysplastic Syndrome companies working in the treatment market, visit @ Myelodysplastic Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Myelodysplastic Syndrome Market Report Introduction

2. Executive Summary for Myelodysplastic Syndrome

3. SWOT analysis of Myelodysplastic Syndrome

4. Myelodysplastic Syndrome Patient Share (%) Overview at a Glance

5. Myelodysplastic Syndrome Market Overview at a Glance

6. Myelodysplastic Syndrome Disease Background and Overview

7. Myelodysplastic Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Myelodysplastic Syndrome 

9. Myelodysplastic Syndrome Current Treatment and Medical Practices

10. Myelodysplastic Syndrome Unmet Needs

11. Myelodysplastic Syndrome Emerging Therapies

12. Myelodysplastic Syndrome Market Outlook

13. Country-Wise Myelodysplastic Syndrome Market Analysis (2020–2034)

14. Myelodysplastic Syndrome Market Access and Reimbursement of Therapies

15. Myelodysplastic Syndrome Market Drivers

16. Myelodysplastic Syndrome Market Barriers

17.  Myelodysplastic Syndrome Appendix

18. Myelodysplastic Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/medical-devices